Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
NeoGenomics runs specialized labs that test cancer patients' tissue and blood to help doctors pick the right treatment.
NeoGenomics is a cancer-testing company. When someone is diagnosed with cancer, or a doctor suspects it, a piece of their tumor or a sample of their blood gets sent to a lab. NeoGenomics is one of the big labs that runs those tests, and the results help doctors figure out exactly what kind of cancer it is and which drug is most likely to work. Its customers are mostly oncologists and hospitals, plus drug companies that hire it to help test new cancer medicines.
The tests themselves come in a few flavors. Some look at the DNA inside cancer cells to find specific mutations — the tiny genetic typos that make a tumor grow and that certain drugs are designed to target. Others look at proteins on the surface of cells or examine the cells under a microscope. This is called "precision oncology": instead of giving everyone the same chemotherapy, doctors use test results to match a patient to a treatment aimed at their particular cancer. That's why the testing matters — a single right result can steer a patient toward a drug that works and away from one that won't. NeoGenomics competes with big lab companies like Labcorp and Quest Diagnostics, and with specialized cancer-testing labs such as Foundation Medicine (owned by Roche). Its edge is focus: cancer is essentially all it does. It has grown partly by buying other labs, and in recent years it pushed hard into "next-generation sequencing," the high-tech DNA-reading tests that are becoming the standard of care. The tricky part of the business is that these advanced tests are expensive to develop and run, and reimbursement from insurers doesn't always keep up, which has made profitability a work in progress.
The company is based in Fort Myers, Florida, and its shares trade on Nasdaq. Drug companies are a growing slice of its work: they pay NeoGenomics to test patient samples during clinical trials, which helps them enroll the right patients and get drugs approved faster. That side of the business is lumpier than the everyday clinical testing, but it's a useful hedge — when one part of the market slows, the other can pick up some slack.
Saved answer · last researched 15 Nov 2026